BACKGROUND: Recent reports have linked the survival-promoting effect of CXCR4 to the up regulation of Bcl-2 protein expression. MATERIALS AND METHODS: To further elucidate the relationship between Bcl-2 and CXCR4, tumorigenicity was evaluated in in vitro and in vivo models following treatment with CTCE-9908, a CXCR4 antagonist peptide. RESULTS: In vitro, CTCE-9908 inhibited cellular proliferation in PC-3-Bcl-2 and PC-3-Neo cell lines Furthermore in our xenograft model, CTCE-9908 delivered via daily intraperitoneal injections resulted in a statistically significant reduction in tumor size compared to control (396 + 205 mm(3) vs. 1,010 + 215 mm(3) respectively, p < 0.05) in the Bcl-2 expressing tumors. This reduction was associated with knockdown of VEGF, inhibition of angiogenesis and lymphangiogenesis, and induction of apoptosis. CTCE-9908 therapy was also associated with a marked reduction in intra-tumoral host cells expressing VEGFR1 and CD11b myeloid-derived suppressor cells (MDSC). CONCLUSION: These data show that CXCR4 antagonists represent a valuable addition to the cancer therapeutic arsenal. Such agents may have beneficial synergistic dual-effects in reducing tumor cell proliferation directly, and indirectly through perturbation of the tumor microenvironment. Further studies of the novel CTCE-9908 compound in prostate and other solid tumor inhibition are warranted. Prostate 69: 1460-1469, 2009. (c) 2009 Wiley-Liss, Inc.
BACKGROUND: Recent reports have linked the survival-promoting effect of CXCR4 to the up regulation of Bcl-2 protein expression. MATERIALS AND METHODS: To further elucidate the relationship between Bcl-2 and CXCR4, tumorigenicity was evaluated in in vitro and in vivo models following treatment with CTCE-9908, a CXCR4 antagonist peptide. RESULTS: In vitro, CTCE-9908 inhibited cellular proliferation in PC-3-Bcl-2 and PC-3-Neo cell lines Furthermore in our xenograft model, CTCE-9908 delivered via daily intraperitoneal injections resulted in a statistically significant reduction in tumor size compared to control (396 + 205 mm(3) vs. 1,010 + 215 mm(3) respectively, p < 0.05) in the Bcl-2 expressing tumors. This reduction was associated with knockdown of VEGF, inhibition of angiogenesis and lymphangiogenesis, and induction of apoptosis. CTCE-9908 therapy was also associated with a marked reduction in intra-tumoral host cells expressing VEGFR1 and CD11b myeloid-derived suppressor cells (MDSC). CONCLUSION: These data show that CXCR4 antagonists represent a valuable addition to the cancer therapeutic arsenal. Such agents may have beneficial synergistic dual-effects in reducing tumor cell proliferation directly, and indirectly through perturbation of the tumor microenvironment. Further studies of the novel CTCE-9908 compound in prostate and other solid tumor inhibition are warranted. Prostate 69: 1460-1469, 2009. (c) 2009 Wiley-Liss, Inc.
Authors: Urszula M Domanska; Jennifer C Boer; Hetty Timmer-Bosscha; Marcel A T M van Vugt; Hilde D Hoving; Nathalie M Kliphuis; Stefano Rosati; Henk G van der Poel; Igle Jan de Jong; Elisabeth G E de Vries; Annemiek M E Walenkamp Journal: Clin Exp Metastasis Date: 2014-08-26 Impact factor: 5.150
Authors: Ido D Weiss; Orit Jacobson; Dale O Kiesewetter; John P Jacobus; Lawrence P Szajek; Xiaoyuan Chen; Joshua M Farber Journal: Mol Imaging Biol Date: 2012-02 Impact factor: 3.488
Authors: Dan G Duda; Sergey V Kozin; Nathaniel D Kirkpatrick; Lei Xu; Dai Fukumura; Rakesh K Jain Journal: Clin Cancer Res Date: 2011-02-24 Impact factor: 12.531
Authors: John D Hainsworth; James A Reeves; Joseph R Mace; Edward J Crane; Oday Hamid; John R Stille; Amy Flynt; Stephanie Roberson; John Polzer; Edward R Arrowsmith Journal: Target Oncol Date: 2016-10 Impact factor: 4.493
Authors: Moneeb Ehtesham; Elliot Min; Neil M Issar; Rebecca A Kasl; Imad S Khan; Reid C Thompson Journal: J Neurooncol Date: 2013-03-14 Impact factor: 4.130